These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 20716052

  • 1. Recent advances in the allosteric inhibition of glycogen phosphorylase.
    Loughlin WA.
    Mini Rev Med Chem; 2010 Oct; 10(12):1139-55. PubMed ID: 20716052
    [Abstract] [Full Text] [Related]

  • 2. Computation as a tool for glycogen phosphorylase inhibitor design.
    Hayes JM, Leonidas DD.
    Mini Rev Med Chem; 2010 Oct; 10(12):1156-74. PubMed ID: 20716053
    [Abstract] [Full Text] [Related]

  • 3. New inhibitors of glycogen phosphorylase as potential antidiabetic agents.
    Somsák L, Czifrák K, Tóth M, Bokor E, Chrysina ED, Alexacou KM, Hayes JM, Tiraidis C, Lazoura E, Leonidas DD, Zographos SE, Oikonomakos NG.
    Curr Med Chem; 2008 Oct; 15(28):2933-83. PubMed ID: 19075645
    [Abstract] [Full Text] [Related]

  • 4. Advances in glycogen phosphorylase inhibitor design.
    Oikonomakos NG, Somsák L.
    Curr Opin Investig Drugs; 2008 Apr; 9(4):379-95. PubMed ID: 18393105
    [Abstract] [Full Text] [Related]

  • 5. Identification, synthesis, and characterization of new glycogen phosphorylase inhibitors binding to the allosteric AMP site.
    Kristiansen M, Andersen B, Iversen LF, Westergaard N.
    J Med Chem; 2004 Jul 01; 47(14):3537-45. PubMed ID: 15214781
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of glycogen phosphorylase in the context of type 2 diabetes, with focus on recent inhibitors bound at the active site.
    Praly JP, Vidal S.
    Mini Rev Med Chem; 2010 Oct 01; 10(12):1102-26. PubMed ID: 20716051
    [Abstract] [Full Text] [Related]

  • 7. Glycogen phosphorylase as a molecular target for type 2 diabetes therapy.
    Oikonomakos NG.
    Curr Protein Pept Sci; 2002 Dec 01; 3(6):561-86. PubMed ID: 12470212
    [Abstract] [Full Text] [Related]

  • 8. Discovery and evaluation of novel benzazepinone derivatives as glycogen phosphorylase inhibitors with potent activity.
    Wang Y, Yan Z, Guo Y, Zhang L.
    Future Med Chem; 2021 May 01; 13(10):897-909. PubMed ID: 33906369
    [Abstract] [Full Text] [Related]

  • 9. Physiological control of liver glycogen metabolism: lessons from novel glycogen phosphorylase inhibitors.
    Agius L.
    Mini Rev Med Chem; 2010 Oct 01; 10(12):1175-87. PubMed ID: 20716056
    [Abstract] [Full Text] [Related]

  • 10. Synthesis of N-glucopyranosidic derivatives as potential inhibitors that bind at the catalytic site of glycogen phosphorylase.
    Gimisis T.
    Mini Rev Med Chem; 2010 Oct 01; 10(12):1127-38. PubMed ID: 20716054
    [Abstract] [Full Text] [Related]

  • 11. Glucose analog inhibitors of glycogen phosphorylases as potential antidiabetic agents: recent developments.
    Somsák L, Nagya V, Hadady Z, Docsa T, Gergely P.
    Curr Pharm Des; 2003 Oct 01; 9(15):1177-89. PubMed ID: 12769745
    [Abstract] [Full Text] [Related]

  • 12. Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).
    Donnier-Maréchal M, Vidal S.
    Expert Opin Ther Pat; 2016 Oct 01; 26(2):199-212. PubMed ID: 26666989
    [Abstract] [Full Text] [Related]

  • 13. The structure of brain glycogen phosphorylase-from allosteric regulation mechanisms to clinical perspectives.
    Mathieu C, Dupret JM, Rodrigues Lima F.
    FEBS J; 2017 Feb 01; 284(4):546-554. PubMed ID: 27782369
    [Abstract] [Full Text] [Related]

  • 14. A New Potent Inhibitor of Glycogen Phosphorylase Reveals the Basicity of the Catalytic Site.
    Mamais M, Degli Esposti A, Kouloumoundra V, Gustavsson T, Monti F, Venturini A, Chrysina ED, Markovitsi D, Gimisis T.
    Chemistry; 2017 Jul 03; 23(37):8800-8805. PubMed ID: 28493496
    [Abstract] [Full Text] [Related]

  • 15. Synthesis and biological evaluation of asiatic acid derivatives as inhibitors of glycogen phosphorylases.
    Zhang L, Chen J, Gong Y, Liu J, Zhang L, Hua W, Sun H.
    Chem Biodivers; 2009 Jun 03; 6(6):864-74. PubMed ID: 19551727
    [Abstract] [Full Text] [Related]

  • 16. Combined in silico and in vitro studies to identify novel antidiabetic flavonoids targeting glycogen phosphorylase.
    Brás NF, Neves RPP, Lopes FAA, Correia MAS, Palma AS, Sousa SF, Ramos MJ.
    Bioorg Chem; 2021 Mar 03; 108():104552. PubMed ID: 33357981
    [Abstract] [Full Text] [Related]

  • 17. Glucose-derived spiro-isoxazolines are anti-hyperglycemic agents against type 2 diabetes through glycogen phosphorylase inhibition.
    Goyard D, Kónya B, Chajistamatiou AS, Chrysina ED, Leroy J, Balzarin S, Tournier M, Tousch D, Petit P, Duret C, Maurel P, Somsák L, Docsa T, Gergely P, Praly JP, Azay-Milhau J, Vidal S.
    Eur J Med Chem; 2016 Jan 27; 108():444-454. PubMed ID: 26708111
    [Abstract] [Full Text] [Related]

  • 18. Glucose-based spiro-oxathiazoles as in vivo anti-hyperglycemic agents through glycogen phosphorylase inhibition.
    Goyard D, Kónya B, Czifrák K, Larini P, Demontrond F, Leroy J, Balzarin S, Tournier M, Tousch D, Petit P, Duret C, Maurel P, Docsa T, Gergely P, Somsák L, Praly JP, Azay-Milhau J, Vidal S.
    Org Biomol Chem; 2020 Feb 07; 18(5):931-940. PubMed ID: 31922157
    [Abstract] [Full Text] [Related]

  • 19. Thermodynamic characterization of allosteric glycogen phosphorylase inhibitors.
    Anderka O, Loenze P, Klabunde T, Dreyer MK, Defossa E, Wendt KU, Schmoll D.
    Biochemistry; 2008 Apr 22; 47(16):4683-91. PubMed ID: 18373353
    [Abstract] [Full Text] [Related]

  • 20. Modeling aided design of potent glycogen phosphorylase inhibitors.
    Deng Q, Lu Z, Bohn J, Ellsworth KP, Myers RW, Geissler WM, Harris G, Willoughby CA, Chapman K, McKeever B, Mosley R.
    J Mol Graph Model; 2005 Apr 22; 23(5):457-64. PubMed ID: 15781188
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.